Medical management update: Non-Hodgkin lymphoma

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 107, Issue 1, 2009, Pages

  Mawardi, Hani ^a   Cutler, Corey ^b   Treister, Nathaniel ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLASSIFICATION; DENTAL CARE; HEAD AND NECK TUMOR; HUMAN; MOUTH DISEASE; NONHODGKIN LYMPHOMA;

DENTAL CARE FOR CHRONICALLY ILL; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; MOUTH DISEASES;

EID: 57649225140     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.08.054     Document Type: Article

References (153)

1. Lu P. Staging and classification of lymphoma. Semin Nucl Med 35 (2005) 160-164
2. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
3. American Cancer Society. Cancer Facts and Figures: Non-Hodgkin's lymphoma. 2007. http//www.cancer.org Accessed August 1, 2007
4. Alexander D.D., Mink P.J., Adami H.O., Chang E.T., Cole P., Mandel J.S., et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120 Suppl 12 (2007) 1-39
5. Young G.A., and Iland H.J. Clinical perspectives in lymphoma. Intern Med J 37 (2007) 478-484
6. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
7. Jaffe E.S., Harris N.L., Diebold J., and Muller-Hermelink H.K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111 (1999) S8-S12
8. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 36 (2000) 69-86
9. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5 (2005) 251-262
10. Roix J.J., McQueen P.G., Munson P.J., Parada L.A., and Misteli T. Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 34 (2003) 287-291
11. Offit K., Wong G., Filippa D.A., Tao Y., and Chaganti R.S. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 77 (1991) 1508-1515
12. Johansson B., Mertens F., and Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 86 (1995) 3905-3914
13. Tycko B., and Sklar J. Chromosomal translocations in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells 2 (1990) 1-8
14. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
15. Kuppers R., Klein U., Hansmann M.L., and Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 341 (1999) 1520-1529
16. Horsman D.E., Connors J.M., Pantzar T., and Gascoyne R.D. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30 (2001) 375-382
17. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 88 (1991) 5413-5417
18. Lo Coco F., Gaidano G., Louie D.C., Offit K., Chaganti R.S., and Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82 (1993) 2289-2295
19. Sander C.A., Yano T., Clark H.M., Harris C., Longo D.L., Jaffe E.S., et al. p53 mutation is associated with progression in follicular lymphomas. Blood 82 (1993) 1994-2004
20. Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H., Lenoir G., et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80 (1992) 1781-1787
21. Kalachikov S., Migliazza A., Cayanis E., Fracchiolla N.S., Bonaldo M.F., Lawton L., et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 42 (1997) 369-377
22. Lyons S.F., and Liebowitz D.N. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 25 (1998) 461-475
23. Epstein M.A., Achong B.G., and Barr Y.M. Virus Particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1 (1964) 702-703
24. Davi F., Delecluse H.J., Guiet P., Gabarre J., Fayon A., Gentilhomme O., et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 16 (1998) 3788-3795
25. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55 (1990) 133-270
26. Miyashita E.M., Yang B., Lam K.M., Crawford D.H., and Thorley-Lawson D.A. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80 (1995) 593-601
27. Frangou P., Buettner M., and Niedobitek G. Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands. J Infect Dis 191 (2005) 238-242
28. Harrison T.R., Isselbacher K.J., Fauci A., Braunwald E., Martin J., Kasper D., and Wilson J.D. Harrison's principles of internal medicine. 12th ed. (1991), McGraw-Hill, New York
29. Golman L., and Bennett J.C. Cecil textbook of medicine. 21 ed. (2000), WB Saunders, Philadelphia
30. Anderson T., Chabner B.A., Young R.C., Berard C.W., Garvin A.J., Simon R.M., et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 50 (1982) 2699-2707
31. Filly R., Bland N., and Castellino R.A. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin's disease and non-Hodgkin's lymphoma. Radiology 120 (1976) 277-281
32. Goffinet D.R., Castellino R.A., Kim H., Dorfman R.F., Fuks Z., Rosenberg S.A., et al. Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas. Cancer 32 (1973) 672-681
33. Risdall R., Hoppe R.T., and Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer 44 (1979) 529-542
34. Seymour J.F., Solomon B., Wolf M.M., Janusczewicz E.H., Wirth A., and Prince H.M. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2 (2001) 109-115
35. Woodman R., Shin K., and Pineo G. Primary non-Hodgkin's lymphoma of the brain. A review. Medicine (Baltimore) 64 (1985) 425-430
36. Freeman C.R., Shustik C., Brisson M.L., Meagher-Villemure K., and Dylewski I. Primary malignant lymphoma of the central nervous system. Cancer 58 (1986) 1106-1111
37. Ottinger H., Belka C., Kozole G., Engelhard M., Meusers P., Paar D., et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 54 (1995) 186-194
38. Ghobrial I.M., Wolf R.C., Pereira D.L., Fonseca R., White W.L., Colgan J.P., et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 79 (2004) 169-175
39. Mohren M., Markmann I., Jentsch-Ullrich K., Koenigsmann M., Lutze G., and Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 92 (2005) 1349-1351
40. Conlan M.G., Armitage J.O., Bast M., and Weisenburger D.D. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 67 (1991) 1389-1395
41. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
42. DePena C.A., Van Tassel P., and Lee Y.Y. Lymphoma of the head and neck. Radiol Clin North Am 28 (1990) 723-743
43. Epstein J.B., Epstein J.D., Le N.D., and Gorsky M. Characteristics of oral and paraoral malignant lymphoma: a population-based review of 361 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 (2001) 519-525
44. Kaugars G.E., and Burns J.C. Non-Hodgkin's lymphoma of the oral cavity associated with AIDS. Oral Surg Oral Med Oral Pathol 67 (1989) 433-436
45. van der Waal R.I., Huijgens P.C., van der Valk P., and van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. Int J Oral Maxillofac Surg 34 (2005) 391-395
46. Kemp S., Gallagher G., Kabani S., Noonan V., and O'Hara C. Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) 194-201
47. Leong I.T., Fernandes B.J., and Mock D. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 (2001) 184-193
48. Soderholm A.L., Lindqvist C., Heikinheimo K., Forssell K., and Happonen R.P. Non-Hodgkin's lymphomas presenting through oral symptoms. Int J Oral Maxillofac Surg 19 (1990) 131-134
49. Raut A., Huryn J., Pollack A., and Zlotolow I. Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 (2000) 436-441
50. Rinaggio J., Aguirre A., Zeid M., and Hatton M.N. Swelling of the nasolabial area. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89 (2000) 669-673
51. Hupp J.R., Collins F.J., Ross A., and Myall R.W. A review of Burkitt's lymphoma. Importance of radiographic diagnosis. J Maxillofac Surg 10 (1982) 240-245
52. McKenna R.W., Bloomfield C.D., and Brunning R.D. Nodular lymphoma: bone marrow and blood manifestations. Cancer 36 (1975) 428-440
53. Ankina M.A., Zavitaeva T.A., Panferova T.A., Shakhtarina S.V., and Pavlov V.V. Cytogenetic study of bone marrow and blood cells in patients with non-Hodgkin lymphoma before and after antitumor therapy. Bull Exp Biol Med 143 (2007) 236-239
54. North L.B., Libshitz H.I., and Lorigan J.G. Thoracic lymphoma. Radiol Clin North Am 28 (1990) 745-762
55. Castellino R.A., Hilton S., O'Brien J.P., and Portlock C.S. Non-Hodgkin lymphoma: contribution of chest CT in the initial staging evaluation. Radiology 199 (1996) 129-132
56. Charnsangavej C. Lymphoma of the genitourinary tract. Radiol Clin North Am 28 (1990) 865-877
57. Isasi C.R., Lu P., and Blaufox M.D. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
58. Karam M., Novak L., Cyriac J., Ali A., Nazeer T., and Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107 (2006) 175-183
59. Pangalis G.A., Vassilakopoulos T.P., Boussiotis V.A., and Fessas P. Clinical approach to lymphadenopathy. Semin Oncol 20 (1993) 570-582
60. Hehn S.T., Grogan T.M., and Miller T.P. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 22 (2004) 3046-3052
61. Florentine B.D., Staymates B., Rabadi M., Barstis J., and Black A. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer 107 (2006) 406-416
62. Pappa V.I., Hussain H.K., Reznek R.H., Whelan J., Norton A.J., Wilson A.M., et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol 14 (1996) 2427-2430
63. Ben-Yehuda D., Polliack A., Okon E., Sherman Y., Fields S., Lebenshart P., et al. Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable. J Clin Oncol 14 (1996) 2431-2434
64. Asoglu O., Porter L., Donohue J.H., and Cha S.S. Laparoscopy for the definitive diagnosis of intra-abdominal lymphoma. Mayo Clin Proc 80 (2005) 625-631
65. Foucar K., McKenna R.W., Frizzera G., and Brunning R.D. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer 49 (1982) 888-897
66. Conlan M.G., Bast M., Armitage J.O., and Weisenburger D.D. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 8 (1990) 1163-1172
67. Ponzoni M., and Li C.Y. Isolated bone marrow non-Hodgkin's lymphoma: a clinicopathologic study. Mayo Clin Proc 69 (1994) 37-43
68. Bennett J.M., Cain K.C., Glick J.H., Johnson G.J., Ezdinli E., and O'Connell M.J. The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol 4 (1986) 1462-1469
69. Menon N.C., and Buchanan J.G. Bilateral trephine bone marrow biopsies in Hodgkin's and non-Hodgkin's lymphoma. Pathology 11 (1979) 53-57
70. Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness. Arch Pathol Lab Med 130 (2006) 1850-1858
71. Dunphy C.H., Gardner L.J., Grosso L.E., and Evans H.L. Flow cytometric immunophenotyping in posttransplant lymphoproliferative disorders. Am J Clin Pathol 117 (2002) 24-28
72. Kaleem Z., Hassan A., Pathan M.H., and White G. Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders. Arch Pathol Lab Med 128 (2004) 181-186
73. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
74. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
75. Young G. Rare lymphoma. In: Raghavan D., Brecher M.L., Johnson D., Meropol N.J., Moots P., and Rose P. (Eds). Textbook of uncommon cancer (2006), Wiley, New York 555-568
76. Kasamon Y.L., and Swinnen L.J. Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 16 (2004) 429-435
77. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
78. Lister T.A., Crowther D., Sutcliffe S.B., Glatstein E., Canellos G.P., Young R.C., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
79. Rosenberg S.A. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 61 (1977) 1023-1027
80. Moormeier J.A., Williams S.F., and Golomb H.M. The staging of non-Hodgkin's lymphomas. Semin Oncol 17 (1990) 43-50
81. Brice P., Bastion Y., Lepage E., Brousse N., Haioun C., Moreau P., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997) 1110-1117
82. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
83. Dumontet C., Drai J., Bienvenu J., Berard E.N., Thieblemont C., Bouafia F., et al. Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin's lymphoma. Leukemia 13 (1999) 811-817
84. Pfistner B., Diehl V., Greb A., and Cheson B. International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl 66 (2005) 53-54
85. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
86. Liu Q., Fayad L., Cabanillas F., Hagemeister F.B., Ayers G.D., Hess M., et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24 (2006) 1582-1589
87. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 (1984) 1471-1475
88. Longo D.L. What's the deal with follicular lymphomas?. J Clin Oncol 11 (1993) 202-208
89. Ardeshna K.M., Smith P., Norton A., Hancock B.W., Hoskin P.J., MacLennan K.A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362 (2003) 516-522
90. Gattiker H.H., Wiltshaw E., and Galton D.A. Spontaneous regression in non-Hodgkin's lymphoma. Cancer 45 (1980) 2627-2632
91. Krikorian J.G., Portlock C.S., Cooney P., and Rosenberg S.A. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 46 (1980) 2093-2099
92. Kelsey S.M., Newland A.C., Hudson G.V., and Jelliffe A.M. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 11 (1994) 19-25
93. Wilder R.B., Jones D., Tucker S.L., Fuller L.M., Ha C.S., McLaughlin P., et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51 (2001) 1219-1227
94. McLaughlin P., Hagemeister F.B., Romaguera J.E., Sarris A.H., Pate O., Younes A., et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14 (1996) 1262-1268
95. Peterson B.A., Petroni G.R., Frizzera G., Barcos M., Bloomfield C.D., Nissen N.I., et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21 (2003) 5-15
96. Foran J.M., Gupta R.K., Cunningham D., Popescu R.A., Goldstone A.H., Sweetenham J.W., et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109 (2000) 81-88
97. Heinzerling L.M., Urbanek M., Funk J.O., Peker S., Bleck O., Neuber K., et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 89 (2000) 1835-1844
98. van Oers M.H., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (2006) 3295-3301
99. Dillman R.O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20 (2002) 3545-3557
100. Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101 (2003) 391-398
101. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23 (2005) 6387-6393
102. Shipp M.A., Aquino S.L., and Harris N.L. Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass. N Engl J Med 352 (2005) 1697-1704
103. Petersen F.B., Appelbaum F.R., Hill R., Fisher L.D., Bigelow C.L., Sanders J.E., et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 8 (1990) 638-647
104. Hosing C., Saliba R.M., Korbling M., Acholonu S., McMannis J., Anderlini P., et al. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47 (2006) 1290-1294
105. van Besien K.W., de Lima M., Giralt S.A., Moore Jr. D.F., Khouri I.F., Rondon G., et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19 (1997) 977-982
106. Kim S.W., Tanimoto T.E., Hirabayashi N., Goto S., Kami M., Yoshioka S., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108 (2006) 382-389
107. Nagler A., Slavin S., Varadi G., Naparstek E., Samuel S., and Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25 (2000) 1021-1028
108. Timmerman J.M. Immunotherapy for lymphomas. Int J Hematol 77 (2003) 444-455
109. Tward J., Glenn M., Pulsipher M., Barnette P., and Gaffney D. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48 (2007) 1482-1495
110. Ahmed A.R., Avram M.M., and Duncan L.M. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 349 (2003) 382-391
111. Anhalt G.J. Paraneoplastic pemphigus. Adv Dermatol 12 (1997) 77-96 discussion 7
112. Wade M.S., and Black M.M. Paraneoplastic pemphigus: a brief update. Australas J Dermatol 46 (2005) 1-8 quiz 9-10
113. Anhalt G.J. Paraneoplastic pemphigus. NH. In: Freedberg I.M., Wolff K., Austen K.F., Goldsmith L.A., and Katz S.I. (Eds). Fitzpatrick's dermatology in general medicine. 6th ed. (2003), McGraw-Hill, New York 568-573 EA
114. Nguyen V.T., Ndoye A., Bassler K.D., Shultz L.D., Shields M.C., Ruben B.S., et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 137 (2001) 193-206
115. Borradori L., Lombardi T., Samson J., Girardet C., Saurat J.H., and Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137 (2001) 269-272
116. Gergely L., Varoczy L., Vadasz G., Remenyik E., and Illes A. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 109 (2003) 202-205
117. Brennan M.T., Woo S.B., and Lockhart P.B. Dental treatment planning and management in the patient who has cancer. Dent Clin North Am 52 (2008) 19-37 vii
118. Lerman M.A., Laudenbach J., Marty F.M., Baden L.R., and Treister N.S. Management of oral infections in cancer patients. Dent Clin North Am 52 (2008) 129-153
119. Little J.W., Falace D.A., Miller C.S., and Rhodus N.L. Dental management of the medically compromised patient. 6th ed. (2002), Mosby, St. Louis
120. Brennan M.T., Runyon M.S., Batts J.J., Fox P.C., Kent M.L., Cox T.L., et al. Odontogenic signs and symptoms as predictors of odontogenic infection: a clinical trial. J Am Dent Assoc 137 (2006) 62-66
121. Flynn T.R., Shanti R.M., Levi M.H., Adamo A.K., Kraut R.A., and Trieger N. Severe odontogenic infections, part 1: prospective report. J Oral Maxillofac Surg 64 (2006) 1093-1103
122. Flynn T.R., Shanti R.M., and Hayes C. Severe odontogenic infections, part 2: prospective outcomes study. J Oral Maxillofac Surg 64 (2006) 1104-1113
123. Finlay P.M., Richardson M.D., and Robertson A.G. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 34 (1996) 23-25
124. Epstein J.B., Gorsky M., and Caldwell J. Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002) 671-675
125. Rothan-Tondeur M., Lancien E., Pialleport T., Meaume S., Moulias R., Marzais M., et al. Prevalence of oropharyngeal candidiasis in geriatric inpatients. J Am Geriatr Soc 49 (2001) 1741-1742
126. Davies A.N., Brailsford S., Broadley K., and Beighton D. Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 17 (2002) 79-84
127. Bohme A., and Karthaus M. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Chemotherapy 45 (1999) 315-324
128. Saral R., Ambinder R.F., Burns W.H., Angelopulos C.M., Griffin D.E., Burke P.J., et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99 (1983) 773-776
129. Whitley R.J., Kimberlin D.W., and Roizman B. Herpes simplex viruses. Clin Infect Dis 26 (1998) 541-553 quiz 54-5
130. Erard V., Wald A., Corey L., Leisenring W.M., and Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 196 (2007) 266-270
131. Boeckh M., Kim H.W., Flowers M.E., Meyers J.D., and Bowden R.A. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 107 (2006) 1800-1805
132. Straus S.E., Ostrove J.M., Inchauspe G., Felser J.M., Freifeld A., Croen K.D., et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 108 (1988) 221-237
133. Johnson R.W. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes 10 (2003) 38-45
134. Epstein J.B., Sherlock C.H., and Greenspan J.S. Hairy leukoplakia-like lesions following bone-marrow transplantation. AIDS 5 (1991) 101-102
135. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44 (2000) 2811-2815
136. Taber D.J., Ashcraft E., Baillie G.M., Berkman S., Rogers J., Baliga P.K., et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 6 (2004) 101-109
137. Said T., Nampoory M.R., Pacsa A.S., Essa S., Madi N., Fahim N., et al. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. Transplant Proc 39 (2007) 997-999
138. Lalla R.V., Sonis S.T., and Peterson D.E. Management of oral mucositis in patients who have cancer. Dent Clin North Am 52 (2008) 61-77 viii
139. Lark R.L., McNeil S.A., VanderHyde K., Noorani Z., Uberti J., and Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 33 (2001) 338-343
140. Tunkel A.R., and Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34 (2002) 1524-1529
141. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
142. Schubert M.M., and Correa M.E. Oral graft-versus-host disease. Dent Clin North Am 52 (2008) 79-109 viii-ix
143. Couriel D., Carpenter P.A., Cutler C., Bolanos-Meade J., Treister N.S., Gea-Banacloche J., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 (2006) 375-396
144. Bassal M., Mertens A.C., Taylor L., Neglia J.P., Greffe B.S., Hammond S., et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24 (2006) 476-483
145. Demarosi F., Lodi G., Carrassi A., Soligo D., and Sardella A. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 41 (2005) 865-877
146. Simon M., Bartram C.R., Friedrich W., Arnold R., Schmeiser T., Hampl W., et al. Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical, immunobiological and pathological study. Virchows Arch B Cell Pathol Incl Mol Pathol 60 (1991) 307-319
147. Teira P., Agbalika F., Bergeron A., Bernaudin F., Carmagnat M., Peffault de Latour R., et al. Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. Clin Infect Dis 43 (2006) 892-895
148. Elad S., Meyerowitz C., Shapira M.Y., Glick M., Bitan M., and Amir G. Oral posttransplantation lymphoproliferative disorder: an uncommon site for an uncommon disorder. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) 59-64
149. Chao N.J., Berry G.J., Advani R., Horning S.J., Weiss L.M., and Blume K.G. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 55 (1993) 1425-1428
150. Hauke R.J., Greiner T.C., Smir B.N., Vose J.M., Tarantolo S.R., Bashir R.M., et al. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant 21 (1998) 1271-1274
151. Micallef I.N., Chhanabhai M., Gascoyne R.D., Shepherd J.D., Fung H.C., Nantel S.H., et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 22 (1998) 981-987
152. Gross T.G., Steinbuch M., DeFor T., Shapiro R.S., McGlave P., Ramsay N.K., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 23 (1999) 251-258
153. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., and Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99 (2002) 3909-3915